The objective of the Ontario Steering Committee for Cancer Drug Programs is to provide evidence based clinical, health research and health economic guidance to the Executive Officer (EO) of Ontario Public Drug Programs (OPDP) on: provincial cancer drug funding policies and decisions, program evaluation and drug-specific studies, and enhancements to cancer drug programs or initiatives in Ontario.
Report Recommends Consistent Approach to Providing Unfunded IV Cancer Drugs to Patients in Ontario Hospitals Would ensure highest standard of care available in every region
Pages
